Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.48 |
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486184 | 1.00 | HSD17B10 (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL883030 | 1.00 | HSD17B10 (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| Hydrochloric Acid SCHEMBL29889454 | 0.98 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL2737884 | 0.95 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL2898129 | 0.95 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL88684 | 0.95 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL6272597 | 0.94 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL3467497 | 0.94 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL6361642 | 0.94 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL18455416 | 0.94 | FKBP1A (0.57) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463455-B1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LTD (IN) | 2026-04-29 | — | — | EP | disclosed |
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| CN-119775187-A | Melanocortin-4 receptor agonists | 株式会社LG化学 | 2025-04-08 | — | — | CN | disclosed |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| WO-2025000265-A1 | HETEROCYCLIC COMPOUNDS USEFULL AS SOS1 INHIBITOR | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2025-01-02 | — | — | WO | disclosed |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-12-17 | — | — | US | disclosed |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| WO-2004009599-A1 | FIVE-MEMBERED HETEROAROMATIC OLEFINIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NCOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1317428-A1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1303485-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| EP-1303507-A1 | PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002006222-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006224-A1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006271-A1 | PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HSD17B10 2431/4885SMN1; SMN2 913/4885NPC1 1322/4885 |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | HSD17B10 2431/4885SMN1; SMN2 913/4885NPC1 1322/4885 |
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | HSD17B10 3461/4885SMN1; SMN2 4151/4885NPC1 2939/4885 |
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | GRIN2C, SLC1A2, CNR2 | HSD17B10 2416/4885SMN1; SMN2 190/4885NPC1 129/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | HSD17B10 1332/4885SMN1; SMN2 4683/4885NPC1 2666/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | HSD17B10 4088/4885SMN1; SMN2 2671/4885NPC1 1895/4885 |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GRIN2C, CNR2, INA | HSD17B10 593/4885SMN1; SMN2 238/4885NPC1 113/4885 |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | AADAC, CYP3A7, CYP3A5 | HSD17B10 483/4885SMN1; SMN2 4695/4885NPC1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.